Using ultrapure water in hemodialysis delays carpal tunnel syndrome.

Since 1977, our patients have undergone chronic HD with ultra-pure dialysate (UPD), defined as having endotoxin levels below 0.008 ng/ml and less than 1 bacteria/ml of dialysate. We evaluated the incidence of carpal tunnel syndrome (CTS) in three groups of patients. Group I (GI), 84 patients, dialysed for 6.1 +/- 3.2 years (mean +/- SD) with UPD only; Group II (GII), 39 patients, first dialysed for 3.7 +/- 2.3 years with non-UPD and afterwards for 8.4 +/- 2.1 years with UPD; Group III (G III), 103 patients treated for 6 +/- 5.9 years exclusively with non-UPD. All patients were dialysed with cuprophan or cellulose acetate membranes. Results, expressed by Kaplan-Meier actuarial survival curves as the percent of patients without CTS, show that CTS occurred significantly less in GI than in GIII. This may be due to less stimulation of monocytes resulting from the absence of bacteria, endotoxins and pyrogens in the dialysate, which would reduce the stimulation of cytokines release, interleukin 1 and 6, and tumor necrosis factor, known to stimulate beta 2 microglobulin synthesis.

A continuous hemofiltration system using sorbents for hemofiltrate regeneration.

Plasma ultrafiltrate obtained by glomerular filtration undergoes tubular modification which leads to the elimination of toxic substances, excess water and electrolytes, and consequently maintains homeostasis. Using normal urine and the substances it contains as a reference, we have developed a wearable device capable of replacing both the renal excretion function and maintaining fluid and electrolyte equilibrium in uremics within acceptable biological limits. Our device includes a hemofilter allowing continuous plasma ultrafiltration and sorbents obtained from a Redy sorbent cartridge to treat 85% of the ultrafiltrate, whereas 15% of this UF is rejected untreated. After calculating the quantity of ultrafiltrate (about 13 l) containing an amount of waste products of metabolism equivalent to 24-h urine elimination, we determined in vitro the amount of sorbent required to eliminate these waste products from the ultrafiltrate (e.g., 20 g of urea/day) and we have evaluated the quantities of other substances which must be replaced using a tailored diet. This extra-corporeal detoxification process was used in a uremic patient who had been on traditional hemodialysis for the past two years. The continuous treatment permitted maintenance of fluid and electrolyte equilibrium at the desired level and allowed rapid improvement of patient clinical status: elimination uf nausea, vomiting, diarrhea and edema, which had previously reappeared during the interdialytic periods, as well as a rapid decrease in heart size as ascites disappeared. In addition, the patient regained sexual drive and the ability to have an erection. In conclusion, traditional hemodialysis and hemofiltration techniques allow intermittent elimination of products retained by the body and reestablish nearly normal fluid and electrolyte balance.(ABSTRACT TRUNCATED AT 250 WORDS)

Comparison of 15N analysis by optical emission spectrometry and mass spectrometry for clinical studies during total parenteral nutrition.

During total and stable parenteral nutrition, a branched chain amino acid enriched solution containing [15N]leucine was infused into a patient to determine the fate of the nitrogen administered through this formulation. Measurements of 15N isotopic enrichments were performed on the same biological samples (urinary urea, total plasma proteins and albumin) by optical emission spectrometry (OES) and mass spectrometry (MS) to determine if OES with its specific advantages (cost, handling maintenance) constituted even with low enrichments a useful alternative technique to MS considered as the reference method. The average 15N% enrichments are 0.5% for urinary urea, 0.21% for total plasma proteins and 0.14% for albumin. The coefficients of correlation between both series of 15N% enrichment measurements realized by MS and OES vary from 0.999 to 0.998 and 0.988, respectively, for urinary urea, total plasma proteins and albumin. These results show that OES constituted a very useful analytical technique to obtain reliable information in clinical metabolic studies when low 15N enrichments must be determined.

Dialysate sodium control during modeling in hemodialysis.

Dialysate sodium (Na+) modeling in hemodialysis requires precise individual adjustment and control of Na+ dialysate concentration. In practice, variations of Na+ concentration can be important and can affect the accuracy of Na+ modeling. Variations relate mainly to the low accuracy of dialysate concentrate (+/- 2.5% for Na+ is tolerated by the European Pharmacopeias), purity of hemodialysis water (2.17 mEq/L is the limit fixed by the French Pharmacopeia), and precision of the proportioning delivery systems for hemodialysis bath preparation. To minimize these difficulties, this study focused on the following points: (a) Na+ concentration is maintained constant (133 mEq/L) in the dialysate manufacturing unit. In 1982, 268 dialysate preparations (177,000 L) were made, and the mean value for Na+ concentration was 133.1 +/- 0.3 mEq/L with a probability of 99.9%. (b) The purity of the water, especially for Na+, Ca2+, and K+, is controlled for two times a day. (c) The accuracy of the proportioning delivery system is controlled by two conductivity monitors, and the variation of Na+ concentration around 133 mEq/L is smaller than +/- 0.5%. As the composition of the basic dialyzing fluid remains constant before adaptation, conductivity values reflect exactly Na+ variation, and are not affected by variations of other elements (K+, Ca2+, Mg2+) that may occur when modification of the dialysate is used for Na+ modeling. (d) Na+ dialysate concentration is adapted for each patient's need by a bedside monitor with sterile Na+ solutions (5 mol/L).(ABSTRACT TRUNCATED AT 250 WORDS)

Simultaneous plasma levels determination of mexiletine and one of its metabolites by electron capture gas-liquid chromatography.

A sensitive and specific electron capture gas-liquid chromatographic method is developed for the determination in human plasma both of mexiletine and of one of its hydroxymethyl metabolites appearing progressively during the kinetics and the presence of which is characterized by mass spectrometry. This method involves the use of two internal standards and the extraction of the drug and of its metabolite from alkaline plasma with diethyl ether followed by back extraction into sulfuric acid (0.2 N) for clean-up procedure and re-extraction by diethyl ether. The limits of detection of the heptafluorobutyryl derivatives of mexiletine and of its metabolite are 20 and 7 ng/ml of plasma, respectively. The preliminary results of the pharmacokinetic study performed in a cardiological unit after single oral administration and during long-term oral maintenance therapy are described in this paper. The method makes it possible to get a better knowledge of the kinetic behaviour of mexiletine and of its metabolite and contributes to the understanding of the origins of the variable pharmacokinetics of mexiletine in patients.

beta-Adrenoceptor blocking effects and pharmacokinetics of pindolol. A study in hypertensive Africans.

The beta-adrenoceptor blocking effects of pindolol were compared with those of a placebo in a double-blind trial in twelve hypertensive Africans. Heart rate and arterial blood pressure were measured at rest and immediately after exercise, before and at intervals up to 8 h after oral administration of the drugs. Plasma levels of pindolol were also determined. Pindolol reduced systolic blood pressure and antagonised exercised-induced tachycardia. The mean time to peak level of pindolol was 1.9 h and the mean half-life was 4.2 h. Comparison of plasma levels of pindolol and beta-adrenoceptor blocking activity showed good correlation between them. It is concluded that the pharmacokinetics and beta-blocking effects of pindolol in Africans are not dissimilar from published data for other races.

Pharmacokinetics of pindolol in Africans.

The pharmacokinetics of pindolol were determined in 12 hypertensive African subjects after a single oral dose of the drug. The estimated pharmacokinetic parameters do not differ significantly in Africans from the values which have been obtained in other races.